RT Conference Proceedings
T1 SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA trial
A1 Balmana, J.
A1 Pascual, T.
A1 Llop-Guevara, A.
A1 Tolosa, P.
A1 Blancas Lopez-Barajas, I.
A1 Perez Lopez, M. E.
A1 Adamo, B.
A1 Teruel-Garcia, I.
A1 Ponce, J.
A1 Gonzalez-Cordero, M.
A1 Vinas Villaro, G.
A1 Lema Roso, L.
A1 Salvador Bofill, F. J.
A1 Martinez, M. T. M.
A1 Guerrero, A. N. E.
A1 Prat, A.
A1 Serra Elizalde, V.
PB Elsevier
SN 0923-7534
YR 2022
FD 2022-05-05
LK http://hdl.handle.net/10668/21898
UL http://hdl.handle.net/10668/21898
LA en
DS RISalud
RD Apr 5, 2025